<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Radkevich-Brown O</submitter><funding>NCI NIH HHS</funding><pagination>409-17</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3702174</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>59(3)</volume><pubmed_abstract>In situ expression of a foreign antigen and an immune-modulating cytokine by intratumoral DNA electroporation was tested as a cancer therapy regimen. Transgene expression in the tumors was sustained for 2-3 weeks after intratumoral electroporation with mammalian expression plasmid containing firefly luciferase cDNA. Electroporation with cDNA encoding tetanus toxin fragment C (TetC) induced tetanus toxin-binding antibody, demonstrating immune recognition of the transgene product. Intratumoral electroporation with TetC and IL-12 cDNA after mice were treated with CD25 mAb to remove regulatory T cells induced IFN-gamma producing T-cell response to tumor-associated antigen, heavy inflammatory infiltration, regression of established tumors and immune memory to protect mice from repeated tumor challenge. Intratumoral expression of immune-modulating molecules may be most suitable in the neoadjuvant setting to enhance the therapeutic efficacy and provide long-term protection.</pubmed_abstract><journal>Cancer immunology, immunotherapy : CII</journal><pubmed_title>Intratumoral DNA electroporation induces anti-tumor immunity  and tumor regression.</pubmed_title><pmcid>PMC3702174</pmcid><funding_grant_id>CA125680</funding_grant_id><funding_grant_id>R01 CA076340</funding_grant_id><funding_grant_id>R01 CA125680</funding_grant_id><funding_grant_id>CA76340</funding_grant_id><pubmed_authors>Pilon-Thomas S</pubmed_authors><pubmed_authors>Piechocki MP</pubmed_authors><pubmed_authors>Back JB</pubmed_authors><pubmed_authors>Weise AM</pubmed_authors><pubmed_authors>Radkevich-Brown O</pubmed_authors><pubmed_authors>Wei WZ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intratumoral DNA electroporation induces anti-tumor immunity  and tumor regression.</name><description>In situ expression of a foreign antigen and an immune-modulating cytokine by intratumoral DNA electroporation was tested as a cancer therapy regimen. Transgene expression in the tumors was sustained for 2-3 weeks after intratumoral electroporation with mammalian expression plasmid containing firefly luciferase cDNA. Electroporation with cDNA encoding tetanus toxin fragment C (TetC) induced tetanus toxin-binding antibody, demonstrating immune recognition of the transgene product. Intratumoral electroporation with TetC and IL-12 cDNA after mice were treated with CD25 mAb to remove regulatory T cells induced IFN-gamma producing T-cell response to tumor-associated antigen, heavy inflammatory infiltration, regression of established tumors and immune memory to protect mice from repeated tumor challenge. Intratumoral expression of immune-modulating molecules may be most suitable in the neoadjuvant setting to enhance the therapeutic efficacy and provide long-term protection.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Mar</publication><modification>2025-04-04T01:29:22.247Z</modification><creation>2019-03-27T01:12:33Z</creation></dates><accession>S-EPMC3702174</accession><cross_references><pubmed>19730859</pubmed><doi>10.1007/s00262-009-0760-1</doi></cross_references></HashMap>